Cadrenal Therapeutics, Inc. (CVKD) - Form 8-K Summary
Business Context and Reporting Period
Cadrenal Therapeutics, Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on May 7, 2026. The filing serves to disclose the issuance of a press release containing financial information for the quarter ended March 31, 2026. The company's common stock trades on the Nasdaq Capital Market under the symbol CVKD.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that such data is contained within the attached press release (Exhibit 99.1), which is not included in the provided source text.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this Form 8-K. The filing explicitly states that the financial information is located in the attached press release.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933 and will not be incorporated by reference into any other SEC filings by the Company.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific financial results for the quarter ended March 31, 2026.
- Verify the company's status as an emerging growth company and any associated accounting election implications.
- Confirm the trading status of CVKD on the Nasdaq Capital Market.
- Note that the financial data in this filing is not incorporated by reference into future SEC documents.